Alternative Physical Activity Strategies for Breast and Prostate Cancer Survivors
Launched by UNIVERSITY OF TORONTO · Oct 7, 2024
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying different ways for survivors of breast and prostate cancer to be physically active, especially focusing on how these activities affect blood sugar levels. The researchers want to compare two new strategies—doing short bursts of activity after meals and having small activity breaks—against not being active at all and a standard 30-minute walk or strength training session. They hope to find out if these new strategies can help lower blood sugar more effectively and if cancer survivors find them easier and more enjoyable than traditional exercise.
To participate in this study, you must be a postmenopausal woman with breast cancer or a man with prostate cancer, both currently receiving hormone therapy. You should have been on this treatment for at least three months and be considered sedentary, meaning you don’t engage in much physical activity. If you join the trial, you'll be asked to try these different activity strategies and share your experiences, helping researchers understand what works best for cancer survivors like you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Postmenopausal biological females diagnosed with stage I, II, or III breast cancer and currently using aromatase inhibitors (AI)
- • Biological males diagnosed with stage I, II, or III prostate cancer and currently using androgen deprivation therapy (ADT).
- * All participants must meet the following criteria:
- • Taking AI or ADT for at least 3 months prior to start of study participation.
- • Body mass index equal to or greater than 25 kg/m\^2.
- • Self-report consuming three main meals daily.
- • Self-report as being sedentary (i.e., less than 30 minutes/week of moderate-to-vigorous aerobic physical activity and less than twice/week muscle strengthening of major muscle groups in the last three months.
- Exclusion Criteria:
- • If unable or unwilling to receive medical clearance by a physician after being screened for major signs or symptoms of cardiovascular diseases, diabetes, or renal disease and safety to initiate exercise.
- • Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease are taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1. They include pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, and unusual fatigue with usual activities.
- • Safety to initiate exercise will be screened using the Get Active Questionnaire, which is the Canadian Society of Exercise Physiology's endorsed evidence-based pre-screening tool.
- • Using drugs for diabetes management (e.g., exogenous insulin, Ozempic, metformin, etc.) or actively losing weight (i.e., \>5 kg weight loss in past 3 months) from drugs or other reasons
- • Report any injury or other reason for not feeling capable of completing a 30 minute continuous walk or muscle strengthening exercise
- • Unable to access an Ontario Lifelabs location for an overnight fasted blood draw
- • Do not have a smartphone compatible with the applications required to collect data.
- • Cannot read and understand the consent form or communicate in English.
About University Of Toronto
The University of Toronto, a prestigious research institution, serves as a leading sponsor of clinical trials dedicated to advancing medical knowledge and improving patient care. With a commitment to innovation and excellence, the university fosters a collaborative environment that brings together multidisciplinary teams of experts in medicine, pharmacology, and public health. Through rigorous research methodologies and ethical standards, the University of Toronto aims to explore new therapies, assess treatment efficacy, and address critical health challenges, ultimately contributing to the global body of scientific knowledge and enhancing healthcare outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported